"We are excited to welcome Karen to the Board of Directors. Karen’s financial expertise and deep understanding of the biotech landscape will play a crucial role in guiding our strategic initiatives ...

The Safety Review Committee monitoring the clinical trial unanimously approved opening of the third cohort based on its favorable review of Cohort 1 and 2 safety and pharmacokinetic data. Additional ...

Prucalopride was safe and effective in increasing the frequency of complete spontaneous bowel movements in patients with ...

TransCode Therapeutics, Inc. , the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the first patient in Cohort 3 of ...

These techniques shorten project timelines by minimizing the need for multiple pilot pharmacokinetic studies. "We are thrilled to announce this expansion of our C2F Center of Excellence," said Dr.

We offer a comprehensive suite of immune checkpoint-related products, including high-quality proteins, inhibitor screening ...

Preliminary U.S. BRIUMVI fourth quarter and full year 2024 net product revenue of $103.6 million and $310 million, respectively Full Year 2025 target total global revenue of approximately $540 ...